Exigent Capital

RenalGuard Solutions develops and markets medical devices for cardiac and vascular care that rapidly remove contrast dyes, which can be toxic to the kidneys, to reduce the risk of contrast-induced nephropathy in at-risk patients undergoing imaging procedures. Its RenalGuard System combines a console and a single-use set to manage fluids during procedures, and RenalGuard Therapy aims to mitigate contrast-related kidney injury. The company distributes its products through a network of distributors in the United States and internationally. It was founded in 1982 and is headquartered in Milford, Massachusetts. The technology has EU approval for general fluid balancing, and European studies have demonstrated effectiveness in preventing CIN, with a pivotal trial in the United States progressing for FDA review.

MaxQ-AI utilizes advanced cognitive analytics and artificial intelligence to deliver real time decision support tools to improve clinical outcomes in acute medical scenarios. The MaxQ team of artificial intelligence, machine learning, deep learning and algorithmic experts and its medical advisory boards in Israel and the United States are achieving breakthroughs in standards of cost and care.

RenalGuard Solutions develops and markets medical devices for cardiac and vascular care that rapidly remove contrast dyes, which can be toxic to the kidneys, to reduce the risk of contrast-induced nephropathy in at-risk patients undergoing imaging procedures. Its RenalGuard System combines a console and a single-use set to manage fluids during procedures, and RenalGuard Therapy aims to mitigate contrast-related kidney injury. The company distributes its products through a network of distributors in the United States and internationally. It was founded in 1982 and is headquartered in Milford, Massachusetts. The technology has EU approval for general fluid balancing, and European studies have demonstrated effectiveness in preventing CIN, with a pivotal trial in the United States progressing for FDA review.

StorePower Inc. is a Chicago-based company founded in 2015 that specializes in developing an online supermarket platform. The platform offers grocery chains a comprehensive suite of tools designed to streamline the online shopping experience, including services for picking, packing, payment processing, click-and-collect, and delivery management. StorePower's technology facilitates automatic stock updates and provides data analysis of shopping traffic, enhancing efficiency for both retailers and consumers. By leveraging years of experience in the e-commerce sector, StorePower provides customized, white-label solutions to help grocery retailers effectively manage their online operations. The company operates as a subsidiary of Direct Eats, Inc.

Revelator Limited is a technology company based in Jerusalem, Israel, that specializes in providing business and marketing cloud solutions tailored for music professionals. Established in 2013, Revelator's platform offers an integrated system for independent artists and record labels, encompassing sales, marketing, accounting, and analytics. The company focuses on bridging traditional music intellectual property with digital assets, utilizing artificial intelligence and machine learning to enhance its offerings. Revelator's solutions facilitate catalog management, metadata handling, delivery and distribution, reporting, royalty management, and analytics. Additionally, the platform supports the transition from Web2 to Web3, enabling on-chain royalty payment processes and automating workflows to help clients reduce costs and mitigate business risks associated with rights administration and royalty distribution.

ImmunArray is a molecular diagnostics company established in 2006, specializing in the development of innovative tests for autoimmune diseases. The company has created a proprietary test that aids in ruling out lupus, a challenging autoimmune condition often confused with other diseases. This test enhances diagnostic accuracy and helps prevent misdiagnosis and inappropriate treatments. Additionally, ImmunArray focuses on in-vitro molecular diagnostics systems that assist physicians in managing complex autoimmune and neurological conditions. Its technology includes microarray devices and informatics designed for profiling patients' immune systems through multi-analyte biomarker-based tests, thereby providing valuable insights for the detection of autoimmune disorders and other diseases.

Liberty SBF is a commercial real estate finance company specializing in small-balance commercial lending. It caters to the financing needs of small businesses that navigate a challenging credit environment. By leveraging a range of loan programs, including conventional, CMBS, and government-backed options, Liberty SBF provides tailored financing solutions for borrowers looking to expand their operations and acquire commercial real estate or other assets. The company emphasizes flexible and customized loan options, ensuring a fast, transparent, and secure online application process, which is particularly beneficial for multifamily and commercial property investors. Through its services, Liberty SBF facilitates access to affordable financing, supporting the growth and development of small businesses.

MaxQ-AI utilizes advanced cognitive analytics and artificial intelligence to deliver real time decision support tools to improve clinical outcomes in acute medical scenarios. The MaxQ team of artificial intelligence, machine learning, deep learning and algorithmic experts and its medical advisory boards in Israel and the United States are achieving breakthroughs in standards of cost and care.